(RGNX) Regenxbio - Ratings and Ratios
Gene,Therapy,AAV,Platform,Pipeline
RGNX EPS (Earnings per Share)
RGNX Revenue
Description: RGNX Regenxbio October 24, 2025
Regenxbio Inc. (NASDAQ:RGNX) is a clinical-stage biotech that commercializes gene-therapy products using its proprietary NAV (AAV-based) delivery platform, targeting genetic disorders primarily in the United States.
Its current pipeline includes: ABBV-RGX-314 for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases (in partnership with AbbVie for non-U.S. markets); RGX-202, a Phase III candidate for Duchenne muscular dystrophy; RGX-121 for mucopolysaccharidosis type II; RGX-111 for mucopolysaccharidosis type I; RGX-181 for late-infantile neuronal ceroid lipofuscinosis type 2; and RGX-381 for the ocular manifestations of CLN2 disease.
Beyond its own product development, Regenxbio licenses the NAV platform to external biotech and pharma firms, generating non-dilutive revenue streams and expanding the technology’s market footprint.
Key quantitative indicators (as of the latest 10-Q) show a cash balance of roughly $250 million, a runway of about 18 months at current burn, and a market capitalization near $1.2 billion, placing the company in the mid-cap tier of the gene-therapy sector, which is projected to grow at a CAGR of 12-15 % through 2030 driven by rising FDA approvals and payer acceptance of AAV-based treatments.
Investors should note that the success of RGX-202’s Phase III readout and the ability to secure additional licensing deals are the primary catalysts that could materially shift the valuation; conversely, any setbacks in trial endpoints or platform safety concerns would materially downgrade upside.
If you’re looking for a deeper, data-driven assessment of Regenxbio’s risk-adjusted upside, ValueRay’s analyst toolkit offers a granular breakdown of the company’s cash-flow projections and comparable peer multiples.
RGNX Stock Overview
| Market Cap in USD | 593m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-09-17 |
RGNX Stock Ratings
| Growth Rating | -27.8% |
| Fundamental | 23.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 18.5% |
| Analyst Rating | 4.42 of 5 |
RGNX Dividends
Currently no dividends paidRGNX Growth Ratios
| Growth Correlation 3m | 92% |
| Growth Correlation 12m | 34.9% |
| Growth Correlation 5y | -95.5% |
| CAGR 5y | -19.25% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.25 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.48 |
| Sharpe Ratio 12m | -0.95 |
| Alpha | 14.46 |
| Beta | 1.170 |
| Volatility | 80.14% |
| Current Volume | 555k |
| Average Volume 20d | 612.4k |
| Stop Loss | 11.9 (-7.3%) |
| Signal | -0.38 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-175.6m TTM) > 0 and > 6% of Revenue (6% = 9.35m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA 18.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 163.2% (prev 279.0%; Δ -115.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -87.9m > Net Income -175.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.5m) change vs 12m ago 1.74% (target <= -2.0% for YES) |
| Gross Margin 79.94% (prev 42.66%; Δ 37.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 27.08% (prev 15.64%; Δ 11.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.89 (EBITDA TTM -129.9m / Interest Expense TTM 29.8m) >= 6 (WARN >= 3) |
Altman Z'' -7.28
| (A) 0.44 = (Total Current Assets 373.8m - Total Current Liabilities 119.5m) / Total Assets 581.0m |
| (B) -1.72 = Retained Earnings (Balance) -996.9m / Total Assets 581.0m |
| warn (B) unusual magnitude: -1.72 — check mapping/units |
| (C) -0.25 = EBIT TTM -145.8m / Avg Total Assets 575.2m |
| (D) -2.72 = Book Value of Equity -997.7m / Total Liabilities 367.3m |
| Total Rating: -7.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.26
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -16.77% = -5.0 |
| 3. FCF Margin -58.23% = -7.50 |
| 4. Debt/Equity 1.27 = 1.74 |
| 5. Debt/Ebitda -1.48 = -2.50 |
| 6. ROIC - WACC (= -63.94)% = -12.50 |
| 7. RoE -66.95% = -2.50 |
| 8. Rev. Trend 21.78% = 1.63 |
| 9. EPS Trend 67.64% = 3.38 |
What is the price of RGNX shares?
Over the past week, the price has changed by +5.33%, over one month by +30.36%, over three months by +52.68% and over the past year by +41.72%.
Is Regenxbio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGNX is around 11.50 USD . This means that RGNX is currently overvalued and has a potential downside of -10.44%.
Is RGNX a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.3 | 128% |
| Analysts Target Price | 29.3 | 128% |
| ValueRay Target Price | 12.8 | -0.3% |
RGNX Fundamental Data Overview October 20, 2025
P/S = 3.8036
P/B = 2.5011
P/EG = 0.26
Beta = 1.17
Revenue TTM = 155.8m USD
EBIT TTM = -145.8m USD
EBITDA TTM = -129.9m USD
Long Term Debt = 77.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 48.4m USD (from shortTermDebt, last quarter)
Debt = 271.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 192.1m USD (from netDebt column, last quarter)
Enterprise Value = 540.9m USD (592.5m + Debt 271.7m - CCE 323.3m)
Interest Coverage Ratio = -4.89 (Ebit TTM -145.8m / Interest Expense TTM 29.8m)
FCF Yield = -16.77% (FCF TTM -90.7m / Enterprise Value 540.9m)
FCF Margin = -58.23% (FCF TTM -90.7m / Revenue TTM 155.8m)
Net Margin = -112.7% (Net Income TTM -175.6m / Revenue TTM 155.8m)
Gross Margin = 79.94% ((Revenue TTM 155.8m - Cost of Revenue TTM 31.3m) / Revenue TTM)
Gross Margin QoQ = 57.33% (prev 96.14%)
Tobins Q-Ratio = 0.93 (Enterprise Value 540.9m / Total Assets 581.0m)
Interest Expense / Debt = 4.05% (Interest Expense 11.0m / Debt 271.7m)
Taxrate = -0.0% (0.0 / -227.1m)
NOPAT = -145.8m (EBIT -145.8m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 3.13 (Total Current Assets 373.8m / Total Current Liabilities 119.5m)
Debt / Equity = 1.27 (Debt 271.7m / totalStockholderEquity, last quarter 213.7m)
Debt / EBITDA = -1.48 (negative EBITDA) (Net Debt 192.1m / EBITDA -129.9m)
Debt / FCF = -2.12 (negative FCF - burning cash) (Net Debt 192.1m / FCF TTM -90.7m)
Total Stockholder Equity = 262.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.22% (Net Income -175.6m / Total Assets 581.0m)
RoE = -66.95% (Net Income TTM -175.6m / Total Stockholder Equity 262.2m)
RoCE = -42.88% (EBIT -145.8m / Capital Employed (Equity 262.2m + L.T.Debt 77.7m))
RoIC = -55.59% (negative operating profit) (NOPAT -145.8m / Invested Capital 262.2m)
WACC = 8.35% (E(592.5m)/V(864.2m) * Re(10.33%) + D(271.7m)/V(864.2m) * Rd(4.05%) * (1-Tc(-0.0)))
Discount Rate = 10.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.17%
Fair Price DCF = unknown (Cash Flow -90.7m)
EPS Correlation: 67.64 | EPS CAGR: 70.27% | SUE: 4.0 | # QB: 1
Revenue Correlation: 21.78 | Revenue CAGR: -7.56% | SUE: -2.75 | # QB: 0
Additional Sources for RGNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle